Real-world data show reduction in use of urate-lowering therapy among people with type 2 diabetes using SGLT2 inhibitors.

Discover the causes, symptoms, and treatment options for gout—a painful form of arthritis predominantly affecting men.

SGLT2 inhibitors may help reduce the risk of nephrolithiasis in patients with type 2 diabetes, including those with co-existing gout. Recent large-scale studies support that sodium-glucose ...

WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for ...

Common treatments, such as statins, are effective at lowering LDL cholesterol and have also shown to reduce inflammation, ...

Amgen today announced the presentation of new data across its rare disease portfolio and pipeline at the annual American College of Rheumatology (ACR) Convergence 2024 conference in Washington, D.C., ...

Like a fire alarm sending signals to evacuate a smoky building, the immune system has internal guards to help the body sense ...

For patients with nephrolithiasis, sodium-glucose cotransporter-2 (SGLT-2) inhibitor use is associated with a reducti ...

Gout causes sudden flares of joint pain, which often arise during the nighttime, and in the big toe, though it may affect other joints including the ankles | Genetics And Genomics ...

A new study has found that SGLT-2 inhibitor drugs for type 2 diabetes may also reduce the risk of kidney stones and gout. These painful conditions are ...

Arthritis is a common acute or chronic condition affecting the joints and surrounding tissues. It’s estimated that roughly 18 ...

WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi ® ), today announced the presentation of four abstracts that ...